Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

F2G

- PMLiVE

Shionogi launches thrombocytopenia treatment Mulpleo in the UK

New treatment option for patients with severe liver disease

- PMLiVE

Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout

Pivotal mid-stage trial results due later this month

- PMLiVE

Modest meeting sees only two drugs recommended by CHMP

Lilly’s migraine med Emgality receives negative opinion for label extension

- PMLiVE

Shionogi scores FDA approval for new cUTI antibiotic

Pivotal new treatment for adults with complicated urinary tract infection

- PMLiVE

Shionogi planning HQ move from UK

Brexit understood to be main reason for switch

Shionogi aims for digital transformation

Signs up with Accenture for seven-year work programme

- PMLiVE

AstraZeneca’s John Rex joins UK biotech F2G

Takes up the role of chief medical officer at the UK company

- PMLiVE

F2G appoints chief financial officer

Ralf Schmid brings experience from Nabriva Therapeutics

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

- PMLiVE

ViiV bags US approval for HIV blockbuster-in-waiting

Drug combines antiretrovirals with Tivicay

- PMLiVE

Hisamitsu’s Noven unit signs Brisdelle deal with Shionogi

Will co-promote the menopausal hot flushes treatment

- PMLiVE

ViiV wins European approval for Tivicay

HIV treatment licensed in combination with other anti-retroviral drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links